Azithromycin for acute lower respiratory tract infections

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Panpanich, Ratana ^a   Lerttrakarnnon, P ^b   Laopaiboon, M ^b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b NONE

Author keywords

Acute disease; Amoxicillin *therapeutic use ; Amoxicillin potassium clavulanate combination *therapeutic use ; Anti bacterial agents *therapeutic use ; Azithromycin *therapeutic use ; Bronchitis *drug therapy

Indexed keywords

RETRACTED ARTICLE; REVIEW;

EID: 44949242478     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001954.pub3     Document Type: Review

References (48)

1. Balmes 1991 {published data only} *Balmes P, Clerc G, Dupont B, Labram C, Pariente R, Poirier R. Comparative study of azitrhomycin and amoxycillin/clavulonic acid in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology & Infectious Diseases 1991;10(5):437-9.
2. Beghi 1995 {published data only} *Beghi G, Berni F, Carratu L, et al.Efficacy and tolerability of azitrhomycin versus amoxicillin/clavulonic acid in acute purunet exacerbation of chronic bronchitis. Journal of Chemotherapy 1995;7(2):146-52.
3. Biebuyck 1996 {published data only} *Biebuyck XA. Comparison of azitrhomycin and co-amoxyclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Journal of Internal Medical Research 1996;24(5):407-18.
4. Daniel 1991 {published data only} *Daniel R. Simplified treatment of acute lower respiratory tract infection with azitrhomycin: a comparison with erytrhomycin and amoxycillin. European Azithromycin Study Group. Journal of International Medical Research 1991;19(5):373-83.
5. Ferwerda 2001 {published data only} Ferwerda A, Moll HA, Hop WCJ, et al.Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 2001;47:441-6.
6. Gris 1996 {published data only} *Gris P. Once-daily, 3 day azithromycin versus a three -times-daily, 10-day course of co-amoxyclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. Journal of Antimicrobial Chemotherapy 1996;37:93-101.
7. Harris 1998 {published data only} Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safty and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatric Infectious Diseases Journal 1998;17:865-71.
8. Hoepelman 1993 {published data only} Hoepelman AIM, Sips AP, Helmond JLM, Barneveld PWC, Neve AJ, Zwinkels M, et al.A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl E):147-52.
9. Hoepelman 1998 {published data only} Hoepelman IM, Mollers MJ, Schie MH, et al.A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. International Journal of Antimicrobial Agents 1998;9:141-6.
10. Mertens 1992 {published data only} *Mertens JC, van Barneveld PW, Asin HR, Ligtvoet E, Visser MR, Branger T, et al.Double-blind randomized study comparing the efficacies and safeties of a short (3 day) course of azithromycin and a 5 day course of amoxycillin in patients with acute exacerbations of chronic bronchitis. Antimicrobial Agents and Chemotherapy 1992;36 (7):1456-9.
11. Sevieri 1993 {published data only} Sevieri G, Roggi G, Monacci A. A comparison between amoxycillin clavulanic acid and azithromycin in exacerbations of chronic bronchitis sustained by Haemophilus influenzae [Confronto Fra Amoxycillina-Acido Clavulanico E Azitromicina Nelle Riacutizzazione Di Bronchite Cronica Sostenuta Da Haemofilus INfluenzae]. Minerva Pneumologica 1993;32(2):67-70.
12. Suping 2002 {published data only} *Zheng S, Li X. Research of amoxicillin/clavulanic in acute purulent exacerbation of chronic bronchitis compare with azithromycin. Journal of Clinical Pulmonary Medicine 2002;7(3):5-6.
13. Whitlock 1995 {published data only} Whitlock W. Multicenter comparison of azithromycin and amoxycillin/clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease. Current Therapeutic Research Clinical and Experimental 1995;56(10):985-95.
14. Wubbel 1999 {published data only} Wubbel L, Muniz L, Ahmed A, Trujillo M, Carubelli C, Abramo T, et al.Etiology and treatment of community acquired pneumonia in ambulatory children. Pediatric Infectious Disease Journal 1999;18(2):98-104.
15. Zachariah 1996 {published data only} Zachariah J. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of Azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1996;37(Suppl):103-13.
16. Berry 1998 *Berry V, Rhorburn CE, Knott SJ, Woodnutt G. Bacteriological efficacies of three macrolides compared with those of amoxycillinclavulanate against Streptococcus pneumoniae and Haemophilus influenza. Antimicrobical Agents and Chemotherapy 1998;42(12): 3193-9.
17. Bohte 1995 Bohte R, van't Wout JW, Lobatto S, Blusse van Oud Alblas A, Boekhout M, Nauta EH. Efficacy and safety of azithromycin versus benzylpennicillin or erytrhomcin in community acquired pneumonia. European Journal of Clinical Microbiology & Infectious Diseases 1995;14(3):182-7.
18. Bradbury 1993 *Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. Journal of Antimicrobial Chemotherapy 1993; 31(Supplement E):153-62.
19. Ficnar 1997 Ficnar B, Huzjak N, Oreskovic K, Matrapazovski M, Kilnar I. Azithromycin: 3 day versus 5 day course in the treatment of respiratory tract infections in children. Journal of Chemotherapy 1997;9(1):38-43.
20. Gomez 1996 Gomez Campdera JA, ML Navarro Gomez, et al.Azithromycin in the treatment of ambulatory pneumonia in children [Azitromycina en el tratamiento de las neumonias ambulatorias en la infancia]. Acta Pediatrica Espanola 1996;54(8):554-62.
21. Laurent 1996 Laurent. Efficacy, safety and tolerability of azithromycin versus roxithromycinin the treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1996;37(Supplement C):115-24.
22. Lauvau 1997 *Lauvau D, Verbist L, Abrassart C, et al.An open, multicentre, comparative study of the efficacy and safety of azithromycin and coamoxyclav in the treatment of upper and lower respiratory tract infections in children. Journal of International Medical Research 1997;25(5):285-95.
23. Morandini 1993 Morandini G, Perduca M, Zannini G, Foschino MP, Miragliotta G, Carnimeo NS. Clinical efficacy of azithromycin in lower respiratory tract infections. Journal of Chemotherapy 1993;5(1):32-6.
24. Rahav 2004 Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. International Journal of Antimicrobial Agents 2004;24(2):181-4.
25. Roord 1996 Roord J, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective open randomized study comparing efficacies and safeties of a 3 day course of azithromycin and a 10 day course of erythromycin in children with community acquired acute lower respiratory tract infections. Antimicrobial Agents and Chemotherapy 1996;40(12):2765-8.
26. Kogan 2003 Kogan R, Martinez MA, Rubilar L, Paya E, Quevedo I, Puppo H, et al.Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatric Pulmonology 2003;35(2):91-8.
27. Austrian 1994 Austrian R. Confronting drug-resistant pneumococci. Annals of Internal Medicine 1994;121:807-09.
28. Bariffi 1995 Bariffi F, Sanduzzi A, Ponticiello A. Epidemiology of lower respiratory tract infections. Journal of Chemotherapy 1995;7(4):263-76.
29. Bartlett 1998 Bartlett JG, Breiman RF, Mandell LA, File TM. Community-Acquired Pneumonia in Adults: Guidelines for Management. The Infectious Diseases Society of America. Clinical Infectious Diseases 1998;26:811-38.
30. Berntsson 1986 Berntsson E, Lagergard T, Strannegard O, et al.Etiology of community-acquired pneumonia in outpatients. European Journal of Clinical Microbiology 1986;5:446.
31. Brown 1998 Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998;352:1295-302.
32. Dunn 1996 Dunn CJ, Barradell LB. Azithromycin: A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drug 1996;51(3):483-505.
33. Fang 1990 Fang GD, Fine M, Orloff J, et al.New and emerging etiology for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases. Medicine 1990;69(5): 307-16.
34. Goldstein 1996 Goldstein FW, Acar JF. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA Collaborative Surveillance Study: The Alexandes Project Collaborative Groups. Journal of Antimicrobial Chemotherapy 1996;38(Suppl A):71-84.
35. Graffelman 2004 Graffelman AW, Neven AK, Cessie SI, Kroes ACM, Springer MP, Peterhans Broek PJ. Pathogens involved in lower respiratory tract infections in general practice. British Journal of General Practice 2004;54:15-9.
36. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
37. Higgins 2005 Higgins JPT, Green S. Developing and documenting a search strategy for studies and organizing search results. Cochrane Handbook for Systematic Reviews of Interventions 4.2 [updated May 2005]; Section 5. In: HigginsJPT, GreenS editor(s). The Cochrane Library. Vol. Issue 3, Chichester, UK: John Wiley & Sons, Ltd, 2005.
38. Huchon 1998 Huchon G, Woodhead M, Gialdroni-Grassi G, et al.Guidelines for managment of adult community-acquired lower respiratory tract infections. European Respiratory Journal 1998;11:986-91.
39. Knutson 2002 Knutson D, Braun C. Diagnosis and management of acute bronchitis. American Family Physician 2002;65(10):2039-44.
40. Langille 1993 Langille DB, Yates L, Marrie TJ. Serological investigation of pneumonia as it presents to the physician's office. Canadian Journal of Infectious Diseases 1993;4:328.
41. Legnani 1997 Legnani D. Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections. Diagnostic Microbiology and Infectious Disease 1997;27:41-7.
42. Lieberman 1996 Lieberman D, Schlaeffer F, Bolden I, et al.Multiple pathogen in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996;51:179-84.
43. Mandell 1994 Mandell L A. Antibiotics for Pneumonia Therapy. Medical Clinics of North America 1994;78(5):997-1014.
44. Marrie 1996 Marrie TJ, Peeling RW, Fine MJ, et al.Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. American Journal of Medicine 1996;101:508-15.
45. Meehan 1997 Meehan TP, Fine Mj, Krunholz HM, et al.Quality of care, process and outcomes in elderly with pneumonia. JAMA 1997;278:2080-4.
46. Sclar 1994 Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infectious Agents and Disease 1994;3(5):266- 73.
47. Woodhead 1991 Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I. The value of routine microbial investigation in community-acquired pneumonia. Respiratory Medicine 1991;85:313-7.
48. Woodhead 1996 Woodhead M, Gialdroni-Grassi G, Huchon GL, Leophonte P, Manresa F, Schaberg T. Use of Investigations in lower respiratory tract infection in the community: a European survey. European Respiratory Journal 1996;9(8):1596-600.